Elsevier

The Lancet

Volume 356, Issue 9242, 11 November 2000, Page 1659
The Lancet

News
Company sought to block paper's publication

https://doi.org/10.1016/S0140-6736(00)03166-4Get rights and content

References (0)

Cited by (19)

  • Results registries for clinical trials - A milestone on the way to transparency in clinical research?

    2010, Zeitschrift fur Evidenz, Fortbildung und Qualitat im Gesundheitswesen
  • Association of funding and findings of pharmaceutical research at a meeting of a medical professional society

    2004, American Journal of Medicine
    Citation Excerpt :

    A second set of biases may result from the efforts of pharmaceutical companies to promote their products, which may be in conflict with the scientific impartiality among institutional decision-makers (3) and individual investigators (10). These efforts may include supporting biased study designs (e.g., those that include nonequivalent comparison interventions) (14,15), controlling access to and analysis of study data, and censoring or “spinning” the results (16–18). A third potential bias may stem from conflicts between investigators’ duty to conduct research objectively and their desire for professional recognition (e.g., by granting agencies and academic promotion committees) and financial reward.

View all citing articles on Scopus
View full text